NDAORALTABLETPriority Review
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Mechanism of Action
Breast Cancer Resistance Protein Inhibitors
Pharmacologic Class:
Hepatitis C Virus NS5A Inhibitor
Clinical Trials (5)
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
Started Sep 2019
6 enrolled
Hepatitis CHemodialysisNosocomial Infection
Zepatier in Patients with Substance Use
Started Sep 2019
25 enrolled
Hepatitis CHivCoinfection, HIV+1 more
Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant
Started Aug 2018
0Cardiac Transplant DisorderHepatitis C
The Dublin Zepatier Study
Started Mar 2018
3 enrolled
Hepatitis C
Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs
Started Nov 2017
11 enrolled
Hepatitis CMedication Adherence
Loss of Exclusivity
LOE Date
May 4, 2031
62 months away
Patent Expiry
May 4, 2031